Skip to main content
MGRX
NASDAQ Industrial Applications And Services

Mangoceuticals Raises $2.5M via Subsidiary-Level Private Placement Without Diluting MGRX Common Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.492
Mkt Cap
$10.613M
52W Low
$0.162
52W High
$2.75
52W Position info
204% above low
Off High info
82% below high
Rel. Volume
Market data snapshot near publication time

MGRX has more than doubled off its 52-week low of $0.162.

Summary

Mangoceuticals raised $2.5M by selling a 25% stake in its MangoRx IP subsidiary to two accredited investors, receiving $1.75M upfront with no dilution to MGRX common shareholders.


Key Events · Financing and Capital Events · MGRX

  • Subsidiary-Level $2.5M Private Placement

    MangoRx IP Holdings, LLC sold a 25% membership interest to two accredited investors for $2.5M; $1.75M received as of filing date for a 17.5% post-transaction stake.

  • No Dilution to MGRX Common Stock

    The investment is at the subsidiary level — no MGRX common stock, warrants, or other parent-company securities were issued, preserving the public capitalization structure.

  • Second Tranche Due November 28, 2026

    The remaining $750,000 for the final 7.5% interest is payable within 60 days of the initial closing; failure to fund would leave investors at 17.5%.

  • Capital Extends Runway Amid Going Concern

    The $1.75M received compares against $229K in cash reported in the Q2 2026 10-Q, providing meaningful runway for commercialization of the MGX-0024 antiviral patent portfolio.


Analysis · MGRX · Industrial Applications And Services

Mangoceuticals' wholly-owned subsidiary MangoRx IP Holdings sold a 25% membership interest to two accredited investors for $2.5 million, with $1.75 million already received. The deal is structured at the subsidiary level, so no MGRX common stock, warrants, or other parent-company securities are issued — public shareholders avoid dilution. This is meaningful for a company with only $229K in cash as of its last 10-Q and a going-concern warning: the capital extends runway and funds commercialization of the MGX-0024 antiviral patent portfolio. The second tranche of $750K is due by November 28, 2026, and failure to fund would reduce the investors' stake to 17.5%.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MGRX was trading at $0.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.16 to $2.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MGRX - Latest Insights

MGRX
Nov 13, 2026, 5:25 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.155
Real-time Price: $0.1503 info
Change: -$0.0047 (-3%) info
Market Cap: $3.445M info
MGRX
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.2078
Real-time Price: $0.1503 info
Change: -$0.0575 (-28%) info
Market Cap: $3.445M info
MGRX
Nov 06, 2026, 5:25 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.190
Real-time Price: $0.1503 info
Change: -$0.0397 (-21%) info
Market Cap: $3.445M info
MGRX
Nov 06, 2026, 5:25 PM EST
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.190
Real-time Price: $0.1503 info
Change: -$0.0397 (-21%) info
Market Cap: $3.445M info
MGRX
Oct 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.430
Real-time Price: $0.1503 info
Change: -$0.2797 (-65%) info
Market Cap: $3.445M info